SGMT
Sagimet Biosciences Inc. Series A
8.90$
+0.1%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q1 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | +10.0% | -3.0% | – | – | – | – | +0.0% | +2.9% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +10.9% | +74.8% | +8.7% | +7.3% | -14.5% | -23.3% | +4.2% | +6.0% | +14.1% | -7.0% | +20.0% | +100.4% | +12.4% | +7.9% | -52.8% | +34.2% | -30.8% | +3.9% | +64.9% | – | |
| – | +47.6% | +98.8% | -69.9% | -2.2% | +81.7% | +47.8% | +4.5% | +88.7% | -15.2% | -8.0% | +22.0% | -0.6% | -6.4% | +13.7% | +3.4% | -1.6% | -12.4% | +17.0% | -9.2% | – | |
| – | +19.9% | +82.0% | -17.2% | +6.2% | -3.9% | -8.4% | +4.3% | +33.9% | +0.1% | -7.4% | +20.8% | +59.6% | +7.6% | +9.2% | -40.0% | +20.2% | -24.9% | +8.8% | +35.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | +61.0% | -11.9% | -3,513.0% | – | – | – | +62.7% | -479.5% | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.